Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis

NCT03420300 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT03420300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03420300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Lead sponsor
National Taiwan University Hospital
Phase
Phase 4
Overall status
Completed
Start date
June 5, 2018
Completion date
February 3, 2020
Enrollment
40 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c